RecruitingPhase 2

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

United States380 participantsStarted 2025-03-26

Plain-language summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent.
✓. Males or females aged 18 to 75 years.
✓. Diagnosis of hypertension.
✓. Hypertension treatment naive or on maximum 2 anti-HTN medications and able to undergo washout for 4 weeks.
✓. Mean sitting SBP ≥140 mmHg measured by OBPM and mean 24 hr SBP ≥130 mmHg and \<160 mmHg measured by ABPM.
✓. Participants able to understand and comply with study procedures.

Exclusion criteria

✕. Known history of secondary hypertension.
✕. Orthostatic hypotension.
✕. Laboratory parameter assessments outside of range at screening.
✕. Evidence of hepatic disease.
✕. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
✕. Any history of congestive heart failure.
✕. Current or history of intolerance to ACEi and/or ARBs.
✕. Clinically significant cardiac arrhythmias, high-grade AV block and third-degree AV block within 6 months prior to screening.

What they're measuring

Change in Mean 24hr SBP by ABPM

Timeframe: Baseline, Month 3

Trial details

NCT IDNCT06857955

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-01-29

Contact for this trial

Novartis Pharmaceuticals

1-888-669-6682 novartis.email@novartis.com

View on ClinicalTrials.gov More Hypertension trials